Search Results for: First Clinical Milestone Achieved in
Articles
Q BioMed & ChemVeda Announce Potential Chemotherapeutic Breakthrough August 21, 2019
Q BioMed, Inc. and Chemveda Life Sciences recently announce the successful chemical synthesis of a unique natural compound that has shown remarkable efficacy as a potential………
Adaptimmune & Alpine Immune Sciences Announce Collaboration & License Agreement May 17, 2019
Adaptimmune Therapeutics plc and Alpine Immune Sciences, Inc. recently announced a collaboration and license agreement to develop next-generation SPEAR T-cell...RedHill Biopharma Submits NDA for for H. Pylori Infection Drug May 10, 2019
RedHill Biopharma Ltd. recently announced that, following a positive pre-NDA meeting held recently with the US FDA, it has submitted a New Drug Application (NDA) to the FDA for Talicia (RHB-105) for the treatment of H. pylori infection.
Saama Partners With The Leukemia & Lymphoma Society & Unveils New Capabilities for Award-Winning Life Science Analytics Cloud February 21, 2019
Saama Technologies, Inc. recently announced a new partnership with The Leukemia & Lymphoma Society (LLS), the world’s largest nonprofit dedicated...Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA November 21, 2018
Synthetic Biologics, Inc. recently announced it has successfully completed an End-of-Phase 2 meeting with the US FDA to discuss development...Cadent Therapeutics Secures $40 Million Series B Financing to Advance Pipeline November 15, 2018
Cadent Therapeutics recently announced it has raised $40 million in a Series B financing. In addition, the company has appointed...EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ October 18, 2018
EyePoint Pharmaceuticals, Inc. recently announced the US FDA has approved YUTIQ (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious...Akcea & Ionis Report Positive Data From Phase 2 Study Akcea & Ionis Report Positive Data From Phase 2 Study September 26, 2018
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. recently announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).
Axovant Announces Global Licensing Agreement With Benitec Biopharma July 10, 2018
Axovant Sciences recently announced it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma...SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: CDMOs Are Innovating for 21st-Century Medicine June 6, 2018
Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs about the innovations they are developing for next-generation patient care, and how many are making investments that are enabling them to offer more services under one roof.
GSK Signs Strategic Agreement With Orchard Therapeutics April 11, 2018
GSK and Orchard Therapeutics today announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational...Boehringer Ingelheim & OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership April 4, 2018
Boehringer Ingelheim and OSE Immunotherapeutics recently announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172,...Agios & Aurigene Enter Exclusive License Agreement May 4, 2017
Agios Pharmaceuticals, Inc. and Aurigene Discovery Technologies Limited recently announced a global license agreement to research, develop, and commercialize small...Kitov Announces License Agreement for KIT-302 in South Korea March 7, 2017
Kitov Pharmaceuticals Holdings Ltd., an innovative biopharmaceutical company, recently announced it has signed a definitive License Agreement for its lead...Kitov Announces License Agreement for KIT-302 in South Korea March 7, 2017
Kitov Pharmaceuticals Holdings Ltd., an innovative biopharmaceutical company, recently announced it has signed a definitive License Agreement for its lead...COMBINATION PRODUCTS - Device Development for Pharmaceutical & Biologic Combination Products October 4, 2016
Bill Welch says when developing a combination product, there are many things to be considered – relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding user needs, determining product requirements, as well as device manufacturing variation.
BIND Therapeutics Announces Pfizer Exercises Option September 28, 2015
BIND Therapeutics, Inc. recently announced Pfizer Inc. exercised its option to obtain an exclusive license to develop and commercialize an...DNA VACCINES MARKET - DNA Vaccines: Strategic Markets & Emerging Technologies November 17, 2014
Kevin James, Shalini Dewan, MS, and Jon Evans, MBA, say the global market for DNA vaccines is estimated at $305.3 million for 2014 and is forecast to grow at a stellar 54.8% compound annual growth rate (CAGR) to reach $2.7 billion by 2019.
Daiichi Sankyo to Acquire Ambit Biosciences September 30, 2014
Daiichi Sankyo Company, Ltd. and Ambit Biosciences jointly announced they have entered into a definitive merger agreement under which Daiichi...EXECUTIVE INTERVIEW - Array BioPharma: Steadily Moving to Late-Stage Development, Preparing for Commercialization March 31, 2014
Executive Summary: Ron Squarer, Chief Executive Officer of Array BioPharma, talks about the company’s pipeline and evolution into a fully integrated, commercial-stage biopharmaceutical company.
